Results 11 to 20 of about 72,428 (200)
Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway [PDF]
Cell Death and DiseaseSorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren +8 more
doaj +2 more sources
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. [PDF]
PLoS ONE, 2017 BACKGROUND:Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC.
Yuki Haga +7 more
doaj +1 more source
Mechanism of sorafenib resistance associated with ferroptosis in HCC
Frontiers in Pharmacology, 2023 Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades.
Lingling Guo +3 more
semanticscholar +1 more source
Journal of Experimental & Clinical Cancer Research, 2022 Background Hepatocellular carcinoma (HCC) is one of the most malignant tumors and the fourth leading cause of cancer-related death worldwide. Sorafenib is currently acknowledged as a standard therapy for advanced HCC.
Danyang Li +12 more
doaj +1 more source
EClinicalMedicine, 2023 Summary: Background: The evidence of radiofrequency ablation (RFA) following transarterial chemoembolisation (TACE) combined with sorafenib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited.
Xiao-Hui Wang +9 more
doaj +1 more source
Autophagy, 2023 Sorafenib is the most widely used first-line drug for the treatment of the advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance often limits its therapeutic efficacy.
Zhaochen Ma +9 more
semanticscholar +1 more source
Scientific Reports, 2021 Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy.
Shou-Sheng Chu +7 more
doaj +1 more source
Molecular and Cellular Probes, 2023 Backgrounds: Sorafenib-resistance leads to poor prognosis and high mortality in advanced hepatocellular carcinoma (HCC), and this study aims to investigate the functional role of a circular RNA ITCH (circITCH) in regulating the sorafenib-resistance of ...
Xiaodong Li +3 more
doaj +1 more source
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
EMBO Molecular Medicine, 2021 Understanding the mechanisms underlying evasive resistance in cancer is an unmet medical need to improve the efficacy of current therapies. In this study, a combination of shRNA‐mediated synthetic lethality screening and transcriptomic analysis revealed ...
Ruize Gao +10 more
semanticscholar +1 more source
Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
Biology, 2023 Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu +7 more
doaj +1 more source